It has become a common practice to use high doses of ifosfamide together with doxorubicin in the treatment of younger patients with aggressive tumours. Response rates in the region of 50% to 60% have been claimed for various doxorubicin plus ifosfamide regimens, with or without the addition of dacarbazine. For example, Patel et al. [5] reported a 66% response rate using doxorubicin 75 mg/m 2 plus ifosfamide 10 g/m 2 . With the use of granulocyte colony-stimulating factor (G-CSF) febrile neutropenia nevertheless occurred in 31% of cycles. Reichardt et al. [6] reported a response rate of 52%, including complete remissions, using epirubicin 90 mg/m 2 , ifosfamide 12.5 g/m 2 and G-CSF. Leyvraz et al. [7] also published similar results using doxorubicin 90 mg/m 2 plus ifosfamide 10 g/m 2 with granulocyte -macrophage colony stimulating factor, which produced a response rate of 55%. Treatment was complicated by grade 4 neutropenia, sepsis, anaemia and mucositis. These data indicate that selected patients have a relatively high likelihood of response to intensive treatment.
When might such combination treatments be justified? If the goal of treatment is maximum tumour shrinkage, for example in trying to render an inoperable tumour operable, one may be justified in treating intensively. This is likely to be the case before pulmonary metastasectomy, with the additional advantage that one is able to determine the chemosensitivity of the pulmonary metastases, hence knowing whether or not adjuvant post-operative treatment is indicated. In the adjuvant setting one will use a combination in the knowledge that there is a degree of non-cross-resistance between agents. Finally, a patient with rapidly progressive, life-threatening disease should perhaps receive combination treatment if there is insufficient time to investigate the response to individual single agents sequentially. It remains unclear whether this approach has any impact on survival.
This generic approach to the treatment of sarcomas belies the heterogeneity of the disease. The chemosensitivity of different subtypes varies, and response and survival is also influenced by time to development of metastatic disease, performance status, disease grade and age [8] .
Gastrointestinal stromal tumour
The disease
The first major breakthrough in terms of specific therapy for an important subtype of soft tissue sarcoma has been in the treatment of gastrointestinal stromal tumour (GIST).
It is worth remembering that the diagnostic label of GIST is a recent one, and it was not until 1998 that the key immunohistochemical marker, CD117 (KIT), was reported to be a reliable means of identifying the disease [9] . It was in the same year that Hirota et al. [10] identified activating mutations in KIT in a group of GIST patients. We now know that GISTs are the most common mesenchymal tumour of the gastrointestinal tract, predominantly arising in the stomach, with a true incidence in the region of 15 per million per year [11] .
Treatment of GIST
The tyrosine kinase inhibitor imatinib was first developed for the treatment of chronic myeloid leukaemia, in which disease it acts by inhibiting BCR-ABL [12] . In the case of GIST, imatinib strongly inhibits KIT that has been activated by mutations in exon 11 of the gene. This is the most common mutation, as first reported by Hirota, and codes for the intracellular juxtamembrane region, described as an autonomously folding autoinhibitory region. It is now thought that imatinib binding holds the protein in an inactive conformation. Following the initial report by Joenssu et al. [13] of a patient with GIST responding to imatinib, clinical trials began in the USA and Europe. A dose-ranging study was performed in Europe, defining imatinib 800 mg as a well tolerated dose [14] . A phase II trial at 800 mg daily confirmed the efficacy and tolerability of imatinib in patients with GIST, but failed to demonstrate response in other sarcoma subtypes [15] . A randomised phase II trial comparing 400 mg and 600 mg daily was conducted in the USA [16] . These studies confirmed the efficacy of imatinib, demonstrating clinical benefit in 80% of patients, with objective response in 50% to 60%. Subsequently, phase III trials were carried out in Europe and the USA comparing 400 mg and 800 mg. There are early indications that the higher dose might yield improved progressionfree but not overall survival, and that patients progressing on the lower dose may respond to a dose increase [17] .
The molecular biology of the disease is a critical determinant of response. Imatinib is markedly less effective against mutations at sites other than exon 11, or where KIT is wildtype [18] (Table 1) . Heinrich et al. [19] had reported previously that activating mutations in the platelet-derived growth factor alpha (PDGFR-A) gene may also be responsible for driving GISTs, and this mutation could be operating in cases where KIT is not strongly expressed. PDGFR-A is also a substrate for imatinib, which may explain why 10% of patients with wild-type KIT nevertheless respond to treatment.
Much still needs to be learned about the role of imatinib in the preoperative and adjuvant setting.
Other disease-specific therapies in sarcoma
The experience with imatinib confirmed a trend towards investigating disease-specific therapy in sarcomas.
Imatinib has also been demonstrated to have efficacy against dermatofibrosarcoma protuberans (DFSP). DFSP is driven by a translocation resulting the fusion of the COL1A1 and PDGF-B genes, resulting in overexpression of PDGF-B [20] , and imatinib appears to work via its inhibition of PDGFR [21] . Trials will determine the response rate of DFSP to imatinib, which may be useful both for patients with locally recurrent inoperable disease and those who have developed the more aggressive form associated with metastatic spread.
Leiomyosarcomas respond variously to conventional chemotherapy, depending on site and grade. Uterine leiomyosarcoma is a particularly aggressive disease but has been reported to respond well to a high-dose combination of gemcitabine plus docetaxel, supported by G-CSF [22] . In this study, the overall response rate was 53%, including three complete responses. Toxicity was significant, but the rate of neutropenic sepsis was acceptable at 6%. This combination is being compared with gemcitabine alone in a randomised trial, and is also being evaluated against other sarcoma subtypes.
Angiosarcoma of the face and scalp was reported to respond to paclitaxel in a retrospective report of nine patients, eight of whom had complete or partial responses [23] , and recent experience suggests that taxanes may have some broader utility against angiosarcomas, including tumours arising at other sites albeit responses can be short and response is less common than in the face/scalp variety. The pegylated liposomal formulation of doxorubicin (Caelyx w /Doxil w ) has also been reported to demonstrate useful activity in this disease [24] .
Synovial sarcoma has been known to express epidermal growth factor receptors (EGFR) [25] , a fact re-examined recently using microarray technology [26] . A study using the EGFR inhibitor gefitinib in synovial sarcoma is underway in the EORTC STBSG.
Other new agents
Many drugs have been tested in soft tissue sarcoma, such as temozolomide, raltitrexed, etoposide and irinotecan. Anecdotal responses are reported, but they have failed to produce evidence of consistent benefit. Pegylated liposomal doxorubicin has antitumour activity with reduced alopecia, bone marrow suppression and probably reduced cardiotoxicity compared with conventional doxorubicin. However, it does produce skin toxicity, which can be troublesome, mucositis also occurs and the antitumour activity appears equivalent to that of the standard drug [27] . One new agent that does appear to offer a genuine advance is trabectidin (ET-743, Yondelis w ). This is a natural product derived from the marine tunicate Ecteinascidia turbinata. It binds in the minor groove of DNA and selectively inhibits transcription. Cytotoxicity is reduced in cells deficient in nucleotide excision repair [28] . It has shown promising activity in sarcomas refractory to conventional cytotoxics, with a relatively low objective remission rate but a high rate of disease stabilisation, with only limited toxicity [29] .
Adjuvant chemotherapy
In spite of some promising early developments, the prognosis for patients with metastatic sarcoma has altered little over the last 20 years. Adjuvant therapy of sarcomas remains controversial. The meta-analysis published in 1997 failed to show a statistical advantage for adjuvant therapy in terms of overall survival, although there was an improvement in progression-free survival [30] . A small study by the Italian Sarcoma Group has shown a survival benefit in a selected group of patients with high-grade sarcomas of the extremities treated with an intensive regimen [31] . An adjuvant study by the EORTC STBSG has recently closed to accrual, and may add to our knowledge in this area.
Conclusions
Although hopes must lie in the development of new agents for these rare diseases, it should be remembered that there are long-term survivors with metastatic disease [32] . This is due to a variety of factors, including pulmonary metastasectomy and intrinsically indolent disease. However, on occasion sarcomas occur following a complete remission to chemotherapy. Perhaps our improving knowledge of the molecular biology of sarcomas will help to elucidate why this occurs, and help to overcome the resistance to treatment that is common to so many sarcomas at present.
